Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
Editorials & Other Articles
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
Mammoth US health bill aims to approve drugs faster, but concerns linger
Source: The Guardian
Mammoth US health bill aims to approve drugs faster, but concerns linger
As the 21st Century Cures Act heads to a Senate vote, critics
argue it is part of a ‘deregulatory agenda’ that dilutes standards
Jessica Glenza in New York
Wednesday 7 December 2016 11.00 GMT
The US Senate is expected to vote Wednesday on a mammoth health bill that took two years to negotiate and passed through the House as few others do: with broad, bipartisan support.
Like many bipartisan works, the $6.2bn 21st Century Cures Act is chock full of compromises.
Critics argue it is part of a “deregulatory agenda”, that dilutes high Food and Drug Administration (FDA) standards in return for the unrealized promise of biomedical research funding. High-profile liberal senators, such as Democrats Elizabeth Warren and Bernie Sanders, and some consumer groups, have criticized what they see as “giveaways” to the pharmaceutical industry.
Proponents call the bill’s mental health, opioid addiction, and brain and cancer research provisions a boon to public health. Republican backers have heralded the bill as “transformational” and “life-saving”, and some non-profit groups such as the American Cancer Society have also expressed support.
[font size=1]-snip-[/font]
As the 21st Century Cures Act heads to a Senate vote, critics
argue it is part of a ‘deregulatory agenda’ that dilutes standards
Jessica Glenza in New York
Wednesday 7 December 2016 11.00 GMT
The US Senate is expected to vote Wednesday on a mammoth health bill that took two years to negotiate and passed through the House as few others do: with broad, bipartisan support.
Like many bipartisan works, the $6.2bn 21st Century Cures Act is chock full of compromises.
Critics argue it is part of a “deregulatory agenda”, that dilutes high Food and Drug Administration (FDA) standards in return for the unrealized promise of biomedical research funding. High-profile liberal senators, such as Democrats Elizabeth Warren and Bernie Sanders, and some consumer groups, have criticized what they see as “giveaways” to the pharmaceutical industry.
Proponents call the bill’s mental health, opioid addiction, and brain and cancer research provisions a boon to public health. Republican backers have heralded the bill as “transformational” and “life-saving”, and some non-profit groups such as the American Cancer Society have also expressed support.
[font size=1]-snip-[/font]
Read more: https://www.theguardian.com/us-news/2016/dec/07/mammoth-us-health-bill-aims-to-approve-drugs-faster-but-concerns-linger